Literature DB >> 1801057

Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial.

P S Williams1, M E Stevens, G Fass, L Irons, J M Bone.   

Abstract

Ninety-five patients (63 male, 32 female), age 45 +/- 2 years (mean +/- SEM) with chronic renal failure of varied aetiology were randomized to receive either a conventional low protein diet (0.6 g/kg/day protein, 800 mg phosphate; n = 33), a low phosphate diet (providing approximately 1000 mg phosphate plus an orally administered phosphate binder, minimum protein intake 0.8 g/kg/day; n = 30) or to control (minimum protein intake 0.8 g/kg/day, no phosphate restriction; n = 32). Patients were reviewed for a minimum of 6 months before randomization and were withdrawn from the study if plasma creatinine exceeded 900 mumol/l, plasma phosphate was greater than 2.0 mmol/l or at the onset of uraemic symptoms. Following randomization patients were studied for an average of 19 +/- 3 months. Mean plasma creatinine rose from 398 +/- 33 to 600 +/- 50 mumol/l. Dietary protein intake was estimated at 0.69 +/- 0.02 g/kg/day in the low protein group, 1.02 +/- 0.05 in the low phosphate and 1.14 +/- 0.05 in the controls, phosphate intake was 815 +/- 43, 1000 +/- 47, and 1315 +/- 57 mg/day, respectively. Urinary urea excretion and protein catabolic rates were significantly reduced (p less than 0.01) only in those on protein restriction, at 213 +/- 9 mmol/24 hours and 0.71 g/kg/day, respectively. Phosphate excretion was significantly lower (p less than 0.05) in both the low protein group (17.9 +/- 0.8 mmol/24 hours) and the low phosphate group (18.6 +/- 1.0 mmol/24 hours) compared to controls. Changes in body weight, muscle mass and serum transferrin, albumin and immunoglobulins were comparable between the groups. Mean blood pressure following randomization was 150/89 +/- 3/1 (low protein), 148/87 +/- 3/1 (low phosphate) and 146/87 +/- 3/1 (controls). Progression of renal failure was analysed by rate of all of creatinine clearance (ml/min/1.73 m2/month), by rate of deterioration derived from reciprocal plasma creatinine against time plots (1/mmol/year) and to assess individual patient's response to treatment by two phase linear regression ('breakpoint') analysis of reciprocal plasma creatinine/time plots. Progression was analysed only in patients seen for at least 3 months following randomization. The rate of fall of creatinine clearance was not significantly different between the groups (ANOVA): 0.56 +/- 0.08 ml/min/1.73 m2/month (low protein, n = 28), 0.44 +/- 0.07 (low phosphate, n = 23) and 0.69 +/- 0.11 (control, n = 27).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801057

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  17 in total

Review 1.  Nutritional treatment in chronic kidney disease: the concept of nephroprotection.

Authors:  Eleonora Riccio; Antonella Di Nuzzi; Antonio Pisani
Journal:  Clin Exp Nephrol       Date:  2014-10-16       Impact factor: 2.801

2.  Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis.

Authors:  Sankar D Navaneethan; Jun Shao; Jerry Buysse; David A Bushinsky
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-13       Impact factor: 8.237

Review 3.  Diets and enteral supplements for improving outcomes in chronic kidney disease.

Authors:  Kamyar Kalantar-Zadeh; Noël J Cano; Klemens Budde; Charles Chazot; Csaba P Kovesdy; Robert H Mak; Rajnish Mehrotra; Dominic S Raj; Ashwini R Sehgal; Peter Stenvinkel; T Alp Ikizler
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

4.  Prescribed dietary phosphate restriction and survival among hemodialysis patients.

Authors:  Katherine E Lynch; Rebecca Lynch; Gary C Curhan; Steven M Brunelli
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 8.237

Review 5.  Contribution of phosphate and FGF23 to CKD progression.

Authors:  Kyle P Jansson; Alan S L Yu; Jason R Stubbs
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-11       Impact factor: 3.416

Review 6.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 7.  Managing chronic renal insufficiency--intertwined roles of non-nephrologist and nephrologist.

Authors:  Onyekachi Ifudu; Eli A Friedman
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

8.  Protein Diet Restriction Slows Chronic Kidney Disease Progression in Non-Diabetic and in Type 1 Diabetic Patients, but Not in Type 2 Diabetic Patients: A Meta-Analysis of Randomized Controlled Trials Using Glomerular Filtration Rate as a Surrogate.

Authors:  Mahesh Shumsher Rughooputh; Rui Zeng; Ying Yao
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

9.  Low protein diets for non-diabetic adults with chronic kidney disease.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Denis Fouque
Journal:  Cochrane Database Syst Rev       Date:  2018-10-04

10.  Low protein diets for non-diabetic adults with chronic kidney disease.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Denis Fouque
Journal:  Cochrane Database Syst Rev       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.